|1.||Romieu, Pascal: 2 articles (04/2004 - 05/2002)|
|2.||Maurice, Tangui: 2 articles (04/2004 - 05/2002)|
|3.||Popova, O V: 1 article (07/2014)|
|4.||Skrebitsky, V G: 1 article (07/2014)|
|5.||Rogozin, P D: 1 article (07/2014)|
|6.||Kapai, N A: 1 article (07/2014)|
|7.||Solntseva, E I: 1 article (07/2014)|
|8.||Petese, Alessandro: 1 article (02/2014)|
|9.||Collina, Simona: 1 article (02/2014)|
|10.||Salvaneschi, Eleonora: 1 article (02/2014)|
05/30/2011 - "Treatment with PRE-084 afforded neuroprotection following embolic stroke as evidenced by significantly reduced infarct volume and improved behavioural outcome. "
05/30/2011 - "In the present study, rats were subjected to embolic stroke or sham stroke and were treated with the sigma-1 receptor agonist PRE-084 (5mg/kg i.p.) or saline vehicle 3 and 24h after stroke. "
05/30/2011 - "Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats."
|2.||Amnesia (Dissociative Amnesia)
12/01/1994 - "Moreover, the PCP derivative PRE-084, acting selectively at sigma sites, reverses the amnesia induced by a drug acting at the PCP site."
05/01/2002 - "The behavioural efficacy of the selective sigma( 1) agonists igmesine and PRE-084 -- reversion of the scopolamine-induced amnesia in the passive avoidance test; diminution of the immobility duration in the forced swimming test -- were significantly higher in C57BL/6 than in Swiss. "
12/01/1994 - "Furthermore, PRE-084 did not affect scopolamine (1 mg/kg SC) induced amnesia but significantly attenuated mecamylamine (10 mg/kg IP) induced amnesia. "
07/01/1999 - "In particular, the anti-amnesic effects induced by the novel sigma1-receptor agonists, such as (+)-pentazocine, SA4503 and PRE-084, were shown in beta amyloid-peptide-induced, basal forebrain (BF)-lesioned and carbon monoxide (CO)-induced amnesia models and senescence-accelerated mouse (SAM). "
|3.||Ganglion Cysts (Ganglion)
03/17/2011 - "Using patch-clamp techniques in rat retinal slice preparations, we demonstrated that activation of σR1 by SKF10047 (SKF) or PRE-084 suppressed N-methyl-D-aspartate (NMDA) receptor-mediated current responses from both ON and OFF type ganglion cells (GCs), dose-dependently, and the effect could be blocked by the σR1 antagonist BD1047 or the σR antagonist haloperidol. "
|4.||Substance-Related Disorders (Drug Abuse)
|5.||Motor Neuron Disease (Primary Lateral Sclerosis)
|3.||sigma-1 receptor (receptor 1, sigma)
|4.||salicylhydroxamic acid (SHAM)
|7.||Citric Acid (Citrate)
|8.||Interleukin-10 (Interleukin 10)